Cellceutix Corp (OTCQB:CTIX) is based in Beverly, Massachusetts and is a clinical stage biotech company. Results are in from in vivo studies using Kevetrin at Beth Israel Deaconess Medical Center (BIDMC), which is a teaching hospital of Harvard Medical School.
Kevetrin is the flagship drug in the Cellceutix pipeline.
BIDMC combined Kevetrin™ with sunitinib on cell line 786, which is a drug-resistant renal cancer. This drug combination was the first time actual tumor shrinkage was seen in this line.
This is extremely good news since renal cancer is very difficult to treat.
Disclosure: I am long OTCQB:CTIX.